pprom
(2)
Amelia Degenkolb
Amelia Degenkolb is the CEO and co-founder of Novocuff, a Mountain View medical device company building the Cervical Control System, a device designed to stabilize the cervix, retain amniotic fluid and prolong pregnancies threatened by preterm premature rupture of membranes. A biomedical engineer who spent seven years as the first employee and lead engineer at Alydia Health, she helped bring the Jada System for postpartum hemorrhage to market before that company's $240M acquisition by Organon. In July 2024 she raised an oversubscribed $26M Series A to fund a U.S. pivotal trial aimed at reducing preterm births, the leading cause of infant mortality worldwide.
Novocuff, Inc.
Novocuff, Inc. is a clinical-stage maternal health medical device company based in Mountain View, California, building the Novocuff Cervical Control System (CCS) - a device designed to stabilize and close the cervix, retain amniotic fluid, and extend pregnancy in cases of preterm prelabor rupture of membranes (PPROM) and cervical shortening. Founded in 2021 by Amelia Degenkolb and Donald Lee, the company raised an oversubscribed $26M Series A in 2024 (about $28M total) to fund its U.S. multicenter pivotal RETAIN trial, for which it secured FDA IDE approval in September 2025.